12 results about "Antigen capture" patented technology

Described herein are methods and kits for the detection of platelet-activating pathogenic antibodies in samples from patients suspected of having platelet-activating antibodies or non-HIT anti-PF4 antibody mediated syndromes using platelets and polyvinyl sulfonate or salts thereof. Upon platelet activation, thrombospondin-1 (TSP1), a platelet granule protein, is released and can be detected using a TSP1 antigen capture enzyme linked immunosorbent assay (ELISA) to accurately measure platelet activation.

The invention provides a double-antibody directionally-coupled FET (Field Effect Transistor) biosensor and a preparation method thereof, and belongs to the technical field of biosensors. The FET biosensor adopts a reference electrode to provide grid voltage, a buffer solution is a conductive electrolyte, the FET biosensor comprises a field effect transistor, a capture antibody and a detection antibody, the field effect transistor is composed of a source electrode, a drain electrode and a channel between the source electrode and the drain electrode, the bottom layer of the channel is an indium oxide thin film layer, the indium oxide thin film layer is modified with amino, and the detection antibody is a detection antibody. An amino-modified channel is obtained; carrying out passivation treatment on the source electrode and the drain electrode by adopting a mercaptan passivator; and cross-linking and fixing the capture antibody and the detection antibody on the channel modified with the amino group through a cross-linking fixing agent to obtain the FET biosensor. The two antibodies are combined according to different epitopes of antigens to form a sandwich structure, and double recognition of the antibodies on target antigens is utilized to enhance antigen capture efficiency and signal enrichment, so that a double-site recognition mode is formed, and low-concentration antigen detection is realized.

The invention relates to the technical field of detection, and relates to a single-molecule protein detection method based on a microarray chip and a chemiluminescence immunoassay technology. An antigen-antibody complex reaction solution is randomly segmented into tens of thousands of microarray holes with the single-hole volume at the pL level by utilizing a microarray chip containing 0.5-200 thousands of micropores with the diameter of 5-30 [mu] m. Each micropore is used as an independent reaction unit for detection and comprises one or zero antigen-antibody compounds, a chromogenic substrate or exciting light is added to collect signal data in all the micropores, and the number of all the antigen-antibody compounds in a reaction system is directly and quantitatively detected according to a Poisson distribution calculation formula. And calculating the concentration of the antigen captured in the microarray chip. The method disclosed by the invention has the advantages of small background signal interference, high sensitivity, specificity, accuracy and precision, simplicity and rapidness in operation, low cost and obvious advantages in the technical field of single molecule detection, and the lower limit of detection reaches fg / ml.

Compositions comprising migratory type 1 conventional dendritic cells in combination with a positively charged antigen capturing nanoparticle comprising a hydrophobic surface and use of the nanoparticle and dendritic cells optionally in combination with an immune checkpoint inhibitor in methods of treating cancer or preventing or reducing the risk of reoccurrence of a cancer in a subject.

The present application relates to the technical field of tumor immunotherapy. The present application provides a responsive antigen capture nano platform, a preparation method and application thereof. The product of the present application is applied by systemic administration such as intravenous injection; can specifically respond to peroxynitrite in the tumor microenvironment, realize the precise activation of the tumor site; can covalently capture tumor-related antigens through high efficiency, deliver the antigens to antigen presenting cells, so as to enhance the anti-tumor immune response; combined with photodynamic therapy can significantly inhibit tumor growth.

The invention discloses an intelligent artificial bionic DC cell nanoparticle nDC-M and a preparation method, application and a detection method thereof. The nano-particle is of a core-shell structure, the inner core is a hypoxia response type nano-micelle of a sound-sensitive agent SP8 and IL-2 for activating T cells to be mature, the outer layer is coated with a mature DC cell membrane, and the nano-particle has the immune recognition characteristic and the treatment function. In a tumor hypoxic microenvironment, the micelle specifically releases SP8 and IL-2; sP8 generates ROS through ultrasonic excitation, tumor cell immunogenicity death is induced, and antigens are released; iL-2 activates proliferation and functions of tumor infiltration lymphocytes; the outer DC cell membrane and the antigen capture functional group enhance the collection and activation of immune cells through surface antigen presentation, and amplify the anti-tumor immune response. By combining sonodynamic therapy and immunoregulation, tumor growth is inhibited, metastatic load is reduced, good biocompatibility and safety are achieved, and a novel bionic delivery system is provided for metastatic tumor immune combined therapy.

The application discloses a BVDV antigen capture ELISA method and kit based on rCD46 and rE2 monoclonal antibodies, and the expression strain is preserved in the China General Microbiological Culture Collection Center on July 24, 2024, with a preservation number of CGMCC NO: 31440; the monoclonal antibody hybridoma cell strain E2mAb strain is preserved in the China General Microbiological Culture Collection Center on October 09, 2024, with a preservation number of CGMCC NO: 46055. The application establishes a BVDV antigen capture ELISA detection method by using a BVDV receptor rCD46 protein as a coating antigen and using HRP-labeled specific rE2 monoclonal antibodies as detection antibodies, and domestic BVDV antigen capture ELISA detection kits based on the receptor rCD46 and the BVDV rE2 monoclonal antibodies are assembled for the first time.

The invention discloses an infectious hematopoietic necrosis virus monoclonal antibody, a hybridoma cell strain and application. The invention relates to the technical field of biology, and provides a complete set of hybridoma cell strain which is composed of a hybridoma cell strain IHNV-N-15-5H3 (CCTCC (China Center for Type Culture Collection) NO: C2024366) and a hybridoma cell strain IHNV-N-151-3A9 (CCTCC NO: C2024367). The invention also provides a complete set of monoclonal antibody secreted by the complete set of hybridoma cell strain. The antigen capture ELISA detection method aiming at the IHNV virus N protein is established by utilizing two monoclonal antibodies, and the effect of the antigen capture ELISA detection method is evaluated to find that the antigen capture ELISA detection method can be used for specifically, quickly and sensitively detecting the infectious hematopoietic necrosis virus.

This invention proposes a microfluidic chip for the combined detection of hepatitis A / hepatitis E virus IgM antibodies and its application. The chip includes a substrate and a cover plate pressed onto the substrate. The substrate and cover plate enclose a microchannel, which is provided with a labeling area and a detection area. The labeling area includes a first labeling area on the lower surface of the cover plate and a second labeling area on the upper surface of the substrate. The detection area includes an HEV-IgM antibody detection area on the lower surface of the cover plate and a HAV-IgM antibody detection area on the upper surface of the substrate. An IgG antibody capture area is provided on the upper surface of the substrate directly below the sample injection well. The IgG antibody capture area contains magnetic microspheres containing anti-human IgG antibodies. The first labeling area contains labeled HEV antigen, the second labeling area contains labeled anti-human IgM antibody, the HEV-IgM antibody detection area contains anti-human IgM antibody, and the HAV-IgM antibody detection area contains HAV antigen. The capture method and the indirect method are used in parallel to achieve the combined detection of IgM antibodies related to the two viruses.

This invention belongs to the field of biodetection technology, specifically relating to an immunoassay kit for early diagnosis of lung cancer and its preparation method. The immunoassay kit includes a chromatographic test strip, lyophilized capture microspheres, a chromogenic stop solution, a quantum dot labeling solution, and a Cell Lysis Buffer. The chromatographic test strip dynamically releases colloidal gold antibodies through a polyester fiber membrane for rapid visual screening. The lyophilized capture microspheres form a high-affinity antigen capture structure through the directional coupling of affinity peptides and dendritic binding domain proteins. The quantum dot labeling solution enables high-fidelity labeling of antibody activity. The chromogenic stop solution releases deep fluorescence and inhibits quenching effects, thus achieving the integration of material interface modification, molecular directional coupling, and signal amplification mechanisms, providing an efficient and reliable auxiliary detection method for early lung cancer screening.

An antibody-antigen capture ELISA-PCR test set for detection of a target protein comprises a first antibody-DNA conjugate having a first antibody which is configured to bind to a target protein; and a first DNA oligo linked to the first antibody; a second antibody-DNA conjugate having a second antibody which is configured to bind to the target protein; and a second DNA oligo linked to the second antibody; and multiple immobilized DNA fragments attached to a designated surface on their attaching ends, wherein the immobilized DNA fragments are complementary to one of the first DNA oligo and the second DNA oligo.